Depression Treatments Reviewed by NeuroInvestment

NeuroInvestment today announced the release of its May issue, which reviews novel treatments being developed for depression. Even though depression can be argued to be the success story of psychopharmacology, the current array of largely similar monoamine-targeting drugs leave 30% of patients without adequate relief, and incur significantly aversive side effects for the majority.
From: biz.yahoo.com